Dr. Nara is currently Chief Executive Officer, President, Chairman & co-founder of Biological Mimetics, Inc., a biotechnology company founded to translate the theory of “Deceptive Imprinting” and the “Immune Refocusing” Technology, discovered by Dr. Nara and colleagues, into preventative vaccines, novel immuno-therapeutics and diagnostics in both human and veterinary medicine. Prior to this position, Dr. Nara was formerly the Section Chief of the Vaccine Resistant Diseases Section, Division of Basic Sciences, Office of the Director at the National Cancer Institute, National Institutes of Health.
Dr. Monsef Benkirane is director of Montpellier Institute of Human Genetics and Lab head at Laboratoire de Virologie Moléculaire in Montpellier, France. Monsef received training in immunology at the University of Marseille, France, and came to the laboratory of our former editor-in-chief Kuan-Teh Jeang at the NIH in 1995, where he worked on HIV-1 transcription and post transcriptional regulation. In 1998, Monsef established his own laboratory at the Human Genetics Institute in Montpellier, France. He published the first paper showing that the transcriptional activity of Tat is regulated by post-translational modifications such as acetylation and ubiquitylation
Dr. Agrewala did his PhD in 1986 from Agra University, Agra, India. In 1989 he joined as a faculty member at the CSIR-Institute of Microbial Technology, Chandigarh, India. He has done pioneer work in the field of Immunology of Infectious Diseases with particular interest in Vaccines. He is a recipient of the highest award in science in India “Shanti Swarup Bhatnagar Award” and a member of Indian Academy of Sciences. Dr. Agrewala has been a visiting scientist at the Hammersmith Hospital, London and Trudeau Institute, NY, USA. Dr. Agrewala has published 67 manuscript in the high impact journals.
Dr. Bernhards R. Ogutu is a Kenyan paediatrician/Clinical pharmarcologist. He is a Chief Research Officer with the Kenya Medical Research Institute (KEMRI). Dr. Ogutu founded the Malaria Diagnostic Centre in response to problems in malaria diagnosis as an endpoint determinant in clinical trials for malaria product development. He has seen the expansion of MDC activities to support research institutions across Africa and beyond and lately National Malaria Control Programs in several Africa countries. Dr Ogutu led the MDC team that participated in WHO malaria diagnosis guidelines and bench aids. Since 2006 Dr. Ogutu has been the Senior Clinical Trialist with the INDEPTH-Network coordinating the clinical trials capacity building across 10 African countries through the INDEPTH program Malaria Clinical Trials Alliance. This created the platform that is conducting the largest phase III RTS,S malaria vaccine clinical trial. The capacity building was in partnership with MMV, MVI and several Northern institutions with funding from the Gates Foundation. Dr. Ogutu co-founded Centre for Research in Therapeutic Sciences (CREATES) which he is the scientific team leader, a consortium involving 4 institutions (KEMRI, Strathmore University, African Centre for Clinical Trials and CSIR of South Africa) to champion product development in Africa with malaria as the flagship program. Dr. Ogutu is the founding He received his MBChB, MMed and PhD from the University of Nairobi.